Assessing PIK3CA and PTEN in Early-Phase Trials with PI3K/AKT/mTOR Inhibitors
Open Access
- 16 January 2014
- journal article
- clinical trial
- Published by Elsevier BV in Cell Reports
- Vol. 6 (2), 377-387
- https://doi.org/10.1016/j.celrep.2013.12.035
Abstract
No abstract availableKeywords
This publication has 39 references indexed in Scilit:
- Molecular Profiling of Patients with Colorectal Cancer and Matched Targeted Therapy in Phase I Clinical TrialsMolecular Cancer Therapeutics, 2012
- BRAF Inhibition in Refractory Hairy-Cell LeukemiaThe New England Journal of Medicine, 2012
- BRAF Mutations in Advanced Cancers: Clinical Characteristics and OutcomesPLOS ONE, 2011
- High Frequency of PIK3R1 and PIK3R2 Mutations in Endometrial Cancer Elucidates a Novel Mechanism for Regulation of PTEN Protein StabilityCancer Discovery, 2011
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialThe Lancet, 2010
- Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysisThe Lancet Oncology, 2010
- Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimusJCI Insight, 2010
- Targeting PI3K signalling in cancer: opportunities, challenges and limitationsNature Reviews Cancer, 2009
- Cancer-specific mutations in PIK3CA are oncogenic in vivoProceedings of the National Academy of Sciences of the United States of America, 2006
- Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid LeukemiaThe New England Journal of Medicine, 2001